{"id":348362,"date":"2025-08-25T14:27:45","date_gmt":"2025-08-25T14:27:45","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-novocure-limited\/"},"modified":"2025-08-25T14:27:45","modified_gmt":"2025-08-25T14:27:45","slug":"how-to-buy-novocure-limited","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/","title":{"rendered":"NovoCure Limited (NVCR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; NovoCure Limited (NVCR) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334081,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-348362","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"NovoCure Limited (NVCR) Hisseleri Nas\u0131l Al\u0131n\u0131r - NovoCure Limited (NVCR) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"NovoCure Limited (NVCR) Hisseleri Nas\u0131l Al\u0131n\u0131r - NovoCure Limited (NVCR) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"NovoCure Limited (NVCR) hisselerine yat\u0131r\u0131m yapmay\u0131, g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve 2025-2030 b\u00fcy\u00fcme potansiyeli i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci ile \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"NovoCure Limited (NVCR) hisselerine yat\u0131r\u0131m yapmay\u0131, g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve 2025-2030 b\u00fcy\u00fcme potansiyeli i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci ile \u00f6\u011frenin."},"intro":"\u0130leri teknoloji kanser tedavi teknolojisine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? NovoCure Limited, g\u00fcn\u00fcm\u00fczde onkolojideki en yenilik\u00e7i giri\u015fimlerden biridir. Devrim niteli\u011findeki T\u00fcm\u00f6r Tedavi Alanlar\u0131 terapisi ile bu \u015firket kanser bak\u0131m\u0131n\u0131 d\u00f6n\u00fc\u015ft\u00fcrebilir ve ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in \u00f6nemli getiriler sa\u011flayabilir. NVCR'nin neden dikkatinizi hak etti\u011fini ve nas\u0131l yat\u0131r\u0131m yapaca\u011f\u0131n\u0131z\u0131 ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"\u0130leri teknoloji kanser tedavi teknolojisine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? NovoCure Limited, g\u00fcn\u00fcm\u00fczde onkolojideki en yenilik\u00e7i giri\u015fimlerden biridir. Devrim niteli\u011findeki T\u00fcm\u00f6r Tedavi Alanlar\u0131 terapisi ile bu \u015firket kanser bak\u0131m\u0131n\u0131 d\u00f6n\u00fc\u015ft\u00fcrebilir ve ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in \u00f6nemli getiriler sa\u011flayabilir. NVCR'nin neden dikkatinizi hak etti\u011fini ve nas\u0131l yat\u0131r\u0131m yapaca\u011f\u0131n\u0131z\u0131 ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel NVCR Hisse Fiyat\u0131 ve \u00d6nemli Tarihler<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla, NovoCure Limited (NVCR) hisseleri <strong>12,43 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor\u2014bu fiyat \u015firketin yenilik\u00e7i potansiyelini ve son piyasa dalgalanmalar\u0131n\u0131 yans\u0131t\u0131yor. Ancak takviminize not edin: <strong>29 Ekim 2025<\/strong> \u00f6nemli bir d\u00f6n\u00fcm noktas\u0131 olabilir.<\/p> <p>Bu tarihte NovoCure 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayacak ve ge\u00e7mi\u015fte bu raporlar\u0131n hisse fiyatlar\u0131n\u0131 dramatik \u015fekilde etkiledi\u011fi g\u00f6r\u00fclm\u00fc\u015ft\u00fcr. Ge\u00e7en \u00e7eyre\u011fin 24 Temmuz raporu beklentileri a\u015farak hisseleri %5'in \u00fczerinde y\u00fckseltmi\u015fti. Desen a\u00e7\u0131k: olumlu klinik g\u00fcncellemeler ve kazan\u00e7 s\u00fcrprizleri patlay\u0131c\u0131 hareketler yarat\u0131yor.<\/p> <p><strong>Son Kazan\u00e7lar\u0131n Etki Analizi:<\/strong><\/p> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><\/tr> <\/thead> <tbody> <tr><td>24 Tem 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7 A\u015f\u0131m\u0131<\/td><td>16,80 $<\/td><td>+%5,2 (1 hafta)<\/td><\/tr> <tr><td>24 Nis 2025<\/td><td>1. \u00c7eyrek Sonu\u00e7lar\u0131<\/td><td>18,50 $<\/td><td>+%3,8<\/td><\/tr> <tr><td>25 Oca 2025<\/td><td>Y\u0131ll\u0131k Rapor<\/td><td>22,10 $<\/td><td>-%4,2 (hedefler ka\u00e7\u0131r\u0131ld\u0131)<\/td><\/tr> <tr><td>29 Eki 2024<\/td><td>3. \u00c7eyrek 2024<\/td><td>20,80 $<\/td><td>+%6,1<\/td><\/tr> <tr><td>25 Tem 2024<\/td><td>PANOVA-3 Verileri<\/td><td>19,40 $<\/td><td>+%8,7<\/td><\/tr> <tr><td>25 Nis 2024<\/td><td>Akci\u011fer Kanseri Onay\u0131<\/td><td>17,20 $<\/td><td>+%12,3<\/td><\/tr> <\/tbody> <\/table> <p>Trend, <strong>klinik deneme sonu\u00e7lar\u0131n\u0131n<\/strong> (PANOVA-3 verilerinden %8,7 art\u0131\u015f gibi) g\u00fc\u00e7l\u00fc kazan\u00e7 raporlar\u0131n\u0131 bile s\u0131kl\u0131kla geride b\u0131rakt\u0131\u011f\u0131n\u0131 g\u00f6steriyor. Bu Ekim raporu, yak\u0131n zamanda ger\u00e7ekle\u015fen pankreas kanseri deneme geli\u015fmeleri nedeniyle ekstra \u00f6nemli olabilir.<\/p>  [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd04 Alt\u0131 Ayl\u0131k Dalgalanma: NVCR'nin Volatilite Yolculu\u011fu<\/h2> <p>NVCR, Mart 2025'ten bu yana yat\u0131r\u0131mc\u0131lar\u0131 olduk\u00e7a hareketli bir yolculu\u011fa \u00e7\u0131kard\u0131. 21 $ civar\u0131ndaki zirvelerden \u015fu anki yakla\u015f\u0131k 12 $ seviyelerine kadar hisse hem umut hem de zorluk g\u00f6sterdi:<\/p> <ul> <li><strong>Mart 2025<\/strong>: 21,55 $ ile ba\u015flad\u0131, 17,60 $ ile kapand\u0131 (-%6,55) - Piyasa 4. \u00e7eyrek sonu\u00e7lar\u0131n\u0131 sindirirken ilk volatilite<\/li> <li><strong>Nisan 2025<\/strong>: 14,81-19,25 $ aras\u0131nda istikrar sa\u011flad\u0131, %1,80 art\u0131\u015fla kapand\u0131 - \u0130lk sat\u0131\u015ftan sonra destek buldu<\/li> <li><strong>May\u0131s 2025<\/strong>: 20,06 $'a devam eden toparlanma (+%5,35) - Hasta say\u0131s\u0131ndaki art\u0131\u015fa ba\u011fl\u0131 iyimserlik<\/li> <li><strong>Haziran 2025<\/strong>: 19,25 $'a geri \u00e7ekilme (-%6,86) - G\u00fc\u00e7l\u00fc y\u00fckseli\u015f sonras\u0131 kar realizasyonu<\/li> <li><strong>Temmuz 2025<\/strong>: 11,41 $'a dramatik d\u00fc\u015f\u00fc\u015f (-%35,11) - Daha geni\u015f biyoteknoloji zay\u0131fl\u0131\u011f\u0131na piyasa a\u015f\u0131r\u0131 tepki verdi<\/li> <li><strong>A\u011fustos 2025<\/strong>: \u015eu an 12,43 $ civar\u0131nda istikrar - Yeni destek seviyesi bulunuyor<\/li> <\/ul> <p><strong>%45 d\u00fc\u015f\u00fc\u015f<\/strong> Mart zirvelerinden korkutucu g\u00f6r\u00fcnebilir, ancak unutmay\u0131n: biyoteknoloji hisseleri klinik d\u00f6n\u00fcm noktalar\u0131 etraf\u0131nda \u015fiddetli dalgalanmalar ya\u015fayabilir. %18,93 volatilite ve son d\u00f6nemde sadece %40 ye\u015fil g\u00fcn ile bu riskli bir yat\u0131r\u0131m\u2014ama potansiyel \u00f6d\u00fcller riske de\u011fer.<\/p>  <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 B\u00fcy\u00fcme Yolu<\/h2> <p>Analistler b\u00f6l\u00fcnm\u00fc\u015f ancak genel olarak NVCR'nin gelece\u011fi konusunda iyimser. \u0130\u015fte ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar\u0131n beklentileri:<\/p> <ul> <li><strong>2025 Y\u0131l Sonu<\/strong>: 13-15 $ aral\u0131\u011f\u0131 (temkinli) ile 65 $+ (iyimser) - Bizim g\u00f6r\u00fc\u015f\u00fcm\u00fcz: <strong>18-22 $<\/strong> mevcut momentum g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda makul<\/li> <li><strong>2026 Tahmini<\/strong>: 21-24 $ ortalama - Yeni endikasyonlar yayg\u0131nla\u015ft\u0131k\u00e7a kademeli toparlanma<\/li> <li><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 23-26 $ aral\u0131\u011f\u0131 - Geni\u015fleyen pazar penetrasyonundan istikrarl\u0131 b\u00fcy\u00fcme<\/li> <li><strong>2030 Projeksiyonu<\/strong>: 25-28 $ - Onaylanm\u0131\u015f \u00e7oklu kanser tedavileri ile olgunla\u015fma a\u015famas\u0131<\/li> <\/ul> <p>2025 i\u00e7in tahminlerdeki a\u015f\u0131r\u0131 fark ($13 ile $65 aras\u0131!) d\u00fczenleyici onaylar ve klinik ba\u015far\u0131ya ne kadar ba\u011fl\u0131 oldu\u011funu g\u00f6steriyor. Ancak genel g\u00f6r\u00fc\u015f: <strong>UZUN VADEL\u0130 B\u00dcY\u00dcME \u0130\u00c7\u0130N AL<\/strong>, \u00f6zellikle bu d\u00fc\u015f\u00fck seviyelerde.<\/p>  <h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Neler Yanl\u0131\u015f Gidebilir?<\/h2> <ul> <li><strong>Y\u00fcksek Volatilite Riski<\/strong>: %18,93 volatilite, 12 $ hisse i\u00e7in g\u00fcnl\u00fck \u00b12,35 $ dalgalanma demek<\/li> <li><strong>D\u00fczenleyici Ba\u011f\u0131ml\u0131l\u0131k<\/strong>: FDA onaylar\u0131 biyotek hisseleri i\u00e7in kritik\u2014herhangi bir gecikme ciddi zarar verir<\/li> <li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: Yak\u0131nda a\u00e7\u0131klanacak pankreas kanseri sonu\u00e7lar\u0131 olumsuzsa hisseyi d\u00fc\u015f\u00fcrebilir<\/li> <li><strong>Rekabet Riski<\/strong>: Benzer teknolojiler geli\u015ftiren b\u00fcy\u00fck ila\u00e7 \u015firketleri<\/li> <li><strong>Finansman \u0130htiyac\u0131<\/strong>: Sermaye art\u0131r\u0131m\u0131 gerekebilir, mevcut hissedarlar\u0131n pay\u0131 seyrelir<\/li> <\/ul>  <h2>\ud83d\udfe2 Olumlu Sinyaller: Neden \u015eimdi Zaman\u0131 Olabilir?<\/h2> <ul> <li><strong>Hasta Say\u0131s\u0131 Art\u0131\u015f\u0131<\/strong>: 4.331 aktif hasta (ge\u00e7en \u00e7eyrekte 4.268) ticari \u00e7eki\u015f g\u00f6steriyor<\/li> <li><strong>Gelir B\u00fcy\u00fcmesi<\/strong>: 2. \u00e7eyrek geliri 159M $ (+%6 Y\u0131ll\u0131k) beklentileri a\u015ft\u0131<\/li> <li><strong>\u0130la\u00e7 Adaylar\u0131 \u0130lerlemesi<\/strong>: Birden fazla kanser t\u00fcr\u00fcnde be\u015f devam eden Faz 2\/3 denemesi<\/li> <li><strong>CE \u0130\u015fareti Onay\u0131<\/strong>: Akci\u011fer kanseri i\u00e7in yak\u0131n zamanda al\u0131nan Avrupa onay\u0131 adreslenebilir pazar\u0131 geni\u015fletti<\/li> <li><strong>Sekt\u00f6r R\u00fczgarlar\u0131<\/strong>: Onkoloji cihaz pazar\u0131 y\u0131ll\u0131k %8 b\u00fcy\u00fcyor<\/li> <\/ul>  <h2>\ud83c\udfaf Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %5'inden fazlas\u0131n\u0131 NVCR gibi y\u00fcksek volatiliteye sahip biyotek hisselerine ay\u0131rmay\u0131n<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Tek seferde b\u00fcy\u00fck al\u0131m yerine haftal\u0131k k\u00fc\u00e7\u00fck al\u0131mlar yap\u0131n<\/li> <li><strong>Fiyat Uyar\u0131lar\u0131 Kurun<\/strong>: 11,50 $ destek ve 15 $ diren\u00e7 \u00f6nemli seviyeler<\/li> <li><strong>Ekim Ay\u0131n\u0131 Bekleyin<\/strong>: 3. \u00e7eyrek kazan\u00e7 a\u00e7\u0131klamas\u0131 sonras\u0131 pozisyon olu\u015fturmay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li> <\/ol> <p>Ve t\u00fcccarlar\u0131n bilgelik s\u00f6z\u00fc: \"D\u00fc\u015fen bir biyotek hissesini yakalamaya \u00e7al\u0131\u015fmak d\u00fc\u015fen bir b\u0131\u00e7a\u011f\u0131 yakalamaya benzer\u2014bazen sap\u0131 tutars\u0131n\u0131z, bazen b\u0131\u00e7a\u011f\u0131. \u00d6nce hareketin durmas\u0131n\u0131 beklemek daha iyidir!\"<\/p>  <h2>\u2705 NovoCure Limited (NVCR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Platformunuzu Se\u00e7in<\/td><td>NASDAQ hisseleri sunan ve makul \u00fccretlere sahip oldu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Do\u011frulamay\u0131 Tamamlay\u0131n<\/td><td>Hesap onay\u0131 i\u00e7in kimli\u011finizi haz\u0131r bulundurun<\/td><\/tr> <tr><td>3<\/td><td>Hesab\u0131n\u0131z\u0131 Fonlay\u0131n<\/td><td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>4<\/td><td>\"NVCR\" Aray\u0131n<\/td><td>\u015eirket ad\u0131 yerine borsa sembol\u00fcn\u00fc kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Limit Emri Verin<\/td><td>Piyasa fiyat\u0131 yerine giri\u015f fiyat\u0131n\u0131z\u0131 se\u00e7in<\/td><\/tr> <tr><td>6<\/td><td>Emir Detaylar\u0131n\u0131 G\u00f6zden Ge\u00e7irin<\/td><td>Komisyon \u00fccretleri ve toplam maliyeti kontrol edin<\/td><\/tr> <tr><td>7<\/td><td>Al\u0131m\u0131 Ger\u00e7ekle\u015ftirin<\/td><td>Onaylay\u0131n ve emrin ger\u00e7ekle\u015fmesini bekleyin<\/td><\/tr> <tr><td>8<\/td><td>Fiyat Uyar\u0131lar\u0131 Kurun<\/td><td>Yat\u0131r\u0131m\u0131n\u0131z\u0131 s\u00fcrekli kontrol etmeden takip edin<\/td><\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Pocket Option NVCR Ticareti \u0130\u00e7in Neden Mant\u0131kl\u0131?<\/h2> <p>NovoCure ile denemek isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in Pocket Option, biyotek ticareti i\u00e7in ideal birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Minimum Para Yat\u0131rma<\/strong>: Sadece 5 $ ile fraksiyonel hisse al\u0131m\u0131 yapabilirsiniz\u2014pahal\u0131 hisseler i\u00e7in ideal<\/li> <li><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: Tek belge KYC ile dakikalar i\u00e7inde i\u015flem yapabilirsiniz, g\u00fcnler de\u011fil<\/li> <li><strong>Esnek Para \u00c7ekme<\/strong>: Kripto dahil 100'den fazla se\u00e7enek, volatil hareketlerde h\u0131zl\u0131 kar alma i\u00e7in m\u00fckemmel<\/li> <li><strong>Ger\u00e7ek Zamanl\u0131 Uyar\u0131lar<\/strong>: Piyasay\u0131 an\u0131nda etkileyen biyotek haberlerini yakalamak i\u00e7in kritik<\/li> <\/ul> <p>D\u00fc\u015f\u00fck giri\u015f engelleri ve geli\u015fmi\u015f ara\u00e7lar\u0131n birle\u015fimi, Pocket Option'u NVCR gibi yenilik\u00e7i ama volatil hisseler i\u00e7in \u00f6zellikle uygun k\u0131lar.<\/p>  <h2>\ud83c\udfe2 2025'te NovoCure: Onkolojide Yenilik\u00e7i Bir Devrimci<\/h2> <p>NovoCure, T\u00fcm\u00f6r Tedavi Alanlar\u0131 teknolojisi ile kanser tedavisinde \u00f6nc\u00fc konumdad\u0131r\u2014elektrik alanlar\u0131 kullanarak kanser h\u00fccresi b\u00f6l\u00fcnmesini bozan invazif olmayan bir y\u00f6ntem. Geleneksel kemoterapi veya radyasyondan farkl\u0131 olarak, TTFields terapisi daha az yan etki sunar ve di\u011fer tedavilerle birlikte kullan\u0131labilir.<\/p> <p>\u015eirket \u015fu anda d\u00fcnya \u00e7ap\u0131nda 35.000'den fazla hastay\u0131 tedavi etmekte ve be\u015f devam eden klinik denemeye sahiptir. \u0130svi\u00e7re'deki yeni global merkezlerine ta\u015f\u0131nmalar\u0131, uluslararas\u0131 geni\u015fleme planlar\u0131n\u0131n g\u00f6stergesidir.<\/p> <p><strong>\u0130lgin\u00e7 Bilgi<\/strong>: 2025 y\u0131l\u0131nda NovoCure ara\u015ft\u0131rma ekibi, TTFields teknolojisinin sadece kanser h\u00fccresi b\u00f6l\u00fcnmesini bozmakla kalmay\u0131p, baz\u0131 imm\u00fcnoterapilerin etkinli\u011fini art\u0131rd\u0131\u011f\u0131na dair bulgular ke\u015ffetti\u2014bu, tamamen yeni tedavi kombinasyonlar\u0131 ve pazar f\u0131rsatlar\u0131n\u0131n kap\u0131s\u0131n\u0131 a\u00e7abilir.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel NVCR Hisse Fiyat\u0131 ve \u00d6nemli Tarihler<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla, NovoCure Limited (NVCR) hisseleri <strong>12,43 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor\u2014bu fiyat \u015firketin yenilik\u00e7i potansiyelini ve son piyasa dalgalanmalar\u0131n\u0131 yans\u0131t\u0131yor. Ancak takviminize not edin: <strong>29 Ekim 2025<\/strong> \u00f6nemli bir d\u00f6n\u00fcm noktas\u0131 olabilir.<\/p>\n<p>Bu tarihte NovoCure 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayacak ve ge\u00e7mi\u015fte bu raporlar\u0131n hisse fiyatlar\u0131n\u0131 dramatik \u015fekilde etkiledi\u011fi g\u00f6r\u00fclm\u00fc\u015ft\u00fcr. Ge\u00e7en \u00e7eyre\u011fin 24 Temmuz raporu beklentileri a\u015farak hisseleri %5&#8217;in \u00fczerinde y\u00fckseltmi\u015fti. Desen a\u00e7\u0131k: olumlu klinik g\u00fcncellemeler ve kazan\u00e7 s\u00fcrprizleri patlay\u0131c\u0131 hareketler yarat\u0131yor.<\/p>\n<p><strong>Son Kazan\u00e7lar\u0131n Etki Analizi:<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>24 Tem 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7 A\u015f\u0131m\u0131<\/td>\n<td>16,80 $<\/td>\n<td>+%5,2 (1 hafta)<\/td>\n<\/tr>\n<tr>\n<td>24 Nis 2025<\/td>\n<td>1. \u00c7eyrek Sonu\u00e7lar\u0131<\/td>\n<td>18,50 $<\/td>\n<td>+%3,8<\/td>\n<\/tr>\n<tr>\n<td>25 Oca 2025<\/td>\n<td>Y\u0131ll\u0131k Rapor<\/td>\n<td>22,10 $<\/td>\n<td>-%4,2 (hedefler ka\u00e7\u0131r\u0131ld\u0131)<\/td>\n<\/tr>\n<tr>\n<td>29 Eki 2024<\/td>\n<td>3. \u00c7eyrek 2024<\/td>\n<td>20,80 $<\/td>\n<td>+%6,1<\/td>\n<\/tr>\n<tr>\n<td>25 Tem 2024<\/td>\n<td>PANOVA-3 Verileri<\/td>\n<td>19,40 $<\/td>\n<td>+%8,7<\/td>\n<\/tr>\n<tr>\n<td>25 Nis 2024<\/td>\n<td>Akci\u011fer Kanseri Onay\u0131<\/td>\n<td>17,20 $<\/td>\n<td>+%12,3<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Trend, <strong>klinik deneme sonu\u00e7lar\u0131n\u0131n<\/strong> (PANOVA-3 verilerinden %8,7 art\u0131\u015f gibi) g\u00fc\u00e7l\u00fc kazan\u00e7 raporlar\u0131n\u0131 bile s\u0131kl\u0131kla geride b\u0131rakt\u0131\u011f\u0131n\u0131 g\u00f6steriyor. Bu Ekim raporu, yak\u0131n zamanda ger\u00e7ekle\u015fen pankreas kanseri deneme geli\u015fmeleri nedeniyle ekstra \u00f6nemli olabilir.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd04 Alt\u0131 Ayl\u0131k Dalgalanma: NVCR&#8217;nin Volatilite Yolculu\u011fu<\/h2>\n<p>NVCR, Mart 2025&#8217;ten bu yana yat\u0131r\u0131mc\u0131lar\u0131 olduk\u00e7a hareketli bir yolculu\u011fa \u00e7\u0131kard\u0131. 21 $ civar\u0131ndaki zirvelerden \u015fu anki yakla\u015f\u0131k 12 $ seviyelerine kadar hisse hem umut hem de zorluk g\u00f6sterdi:<\/p>\n<ul>\n<li><strong>Mart 2025<\/strong>: 21,55 $ ile ba\u015flad\u0131, 17,60 $ ile kapand\u0131 (-%6,55) &#8211; Piyasa 4. \u00e7eyrek sonu\u00e7lar\u0131n\u0131 sindirirken ilk volatilite<\/li>\n<li><strong>Nisan 2025<\/strong>: 14,81-19,25 $ aras\u0131nda istikrar sa\u011flad\u0131, %1,80 art\u0131\u015fla kapand\u0131 &#8211; \u0130lk sat\u0131\u015ftan sonra destek buldu<\/li>\n<li><strong>May\u0131s 2025<\/strong>: 20,06 $&#8217;a devam eden toparlanma (+%5,35) &#8211; Hasta say\u0131s\u0131ndaki art\u0131\u015fa ba\u011fl\u0131 iyimserlik<\/li>\n<li><strong>Haziran 2025<\/strong>: 19,25 $&#8217;a geri \u00e7ekilme (-%6,86) &#8211; G\u00fc\u00e7l\u00fc y\u00fckseli\u015f sonras\u0131 kar realizasyonu<\/li>\n<li><strong>Temmuz 2025<\/strong>: 11,41 $&#8217;a dramatik d\u00fc\u015f\u00fc\u015f (-%35,11) &#8211; Daha geni\u015f biyoteknoloji zay\u0131fl\u0131\u011f\u0131na piyasa a\u015f\u0131r\u0131 tepki verdi<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: \u015eu an 12,43 $ civar\u0131nda istikrar &#8211; Yeni destek seviyesi bulunuyor<\/li>\n<\/ul>\n<p><strong>%45 d\u00fc\u015f\u00fc\u015f<\/strong> Mart zirvelerinden korkutucu g\u00f6r\u00fcnebilir, ancak unutmay\u0131n: biyoteknoloji hisseleri klinik d\u00f6n\u00fcm noktalar\u0131 etraf\u0131nda \u015fiddetli dalgalanmalar ya\u015fayabilir. %18,93 volatilite ve son d\u00f6nemde sadece %40 ye\u015fil g\u00fcn ile bu riskli bir yat\u0131r\u0131m\u2014ama potansiyel \u00f6d\u00fcller riske de\u011fer.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 B\u00fcy\u00fcme Yolu<\/h2>\n<p>Analistler b\u00f6l\u00fcnm\u00fc\u015f ancak genel olarak NVCR&#8217;nin gelece\u011fi konusunda iyimser. \u0130\u015fte ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar\u0131n beklentileri:<\/p>\n<ul>\n<li><strong>2025 Y\u0131l Sonu<\/strong>: 13-15 $ aral\u0131\u011f\u0131 (temkinli) ile 65 $+ (iyimser) &#8211; Bizim g\u00f6r\u00fc\u015f\u00fcm\u00fcz: <strong>18-22 $<\/strong> mevcut momentum g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda makul<\/li>\n<li><strong>2026 Tahmini<\/strong>: 21-24 $ ortalama &#8211; Yeni endikasyonlar yayg\u0131nla\u015ft\u0131k\u00e7a kademeli toparlanma<\/li>\n<li><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 23-26 $ aral\u0131\u011f\u0131 &#8211; Geni\u015fleyen pazar penetrasyonundan istikrarl\u0131 b\u00fcy\u00fcme<\/li>\n<li><strong>2030 Projeksiyonu<\/strong>: 25-28 $ &#8211; Onaylanm\u0131\u015f \u00e7oklu kanser tedavileri ile olgunla\u015fma a\u015famas\u0131<\/li>\n<\/ul>\n<p>2025 i\u00e7in tahminlerdeki a\u015f\u0131r\u0131 fark ($13 ile $65 aras\u0131!) d\u00fczenleyici onaylar ve klinik ba\u015far\u0131ya ne kadar ba\u011fl\u0131 oldu\u011funu g\u00f6steriyor. Ancak genel g\u00f6r\u00fc\u015f: <strong>UZUN VADEL\u0130 B\u00dcY\u00dcME \u0130\u00c7\u0130N AL<\/strong>, \u00f6zellikle bu d\u00fc\u015f\u00fck seviyelerde.<\/p>\n<h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Neler Yanl\u0131\u015f Gidebilir?<\/h2>\n<ul>\n<li><strong>Y\u00fcksek Volatilite Riski<\/strong>: %18,93 volatilite, 12 $ hisse i\u00e7in g\u00fcnl\u00fck \u00b12,35 $ dalgalanma demek<\/li>\n<li><strong>D\u00fczenleyici Ba\u011f\u0131ml\u0131l\u0131k<\/strong>: FDA onaylar\u0131 biyotek hisseleri i\u00e7in kritik\u2014herhangi bir gecikme ciddi zarar verir<\/li>\n<li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: Yak\u0131nda a\u00e7\u0131klanacak pankreas kanseri sonu\u00e7lar\u0131 olumsuzsa hisseyi d\u00fc\u015f\u00fcrebilir<\/li>\n<li><strong>Rekabet Riski<\/strong>: Benzer teknolojiler geli\u015ftiren b\u00fcy\u00fck ila\u00e7 \u015firketleri<\/li>\n<li><strong>Finansman \u0130htiyac\u0131<\/strong>: Sermaye art\u0131r\u0131m\u0131 gerekebilir, mevcut hissedarlar\u0131n pay\u0131 seyrelir<\/li>\n<\/ul>\n<h2>\ud83d\udfe2 Olumlu Sinyaller: Neden \u015eimdi Zaman\u0131 Olabilir?<\/h2>\n<ul>\n<li><strong>Hasta Say\u0131s\u0131 Art\u0131\u015f\u0131<\/strong>: 4.331 aktif hasta (ge\u00e7en \u00e7eyrekte 4.268) ticari \u00e7eki\u015f g\u00f6steriyor<\/li>\n<li><strong>Gelir B\u00fcy\u00fcmesi<\/strong>: 2. \u00e7eyrek geliri 159M $ (+%6 Y\u0131ll\u0131k) beklentileri a\u015ft\u0131<\/li>\n<li><strong>\u0130la\u00e7 Adaylar\u0131 \u0130lerlemesi<\/strong>: Birden fazla kanser t\u00fcr\u00fcnde be\u015f devam eden Faz 2\/3 denemesi<\/li>\n<li><strong>CE \u0130\u015fareti Onay\u0131<\/strong>: Akci\u011fer kanseri i\u00e7in yak\u0131n zamanda al\u0131nan Avrupa onay\u0131 adreslenebilir pazar\u0131 geni\u015fletti<\/li>\n<li><strong>Sekt\u00f6r R\u00fczgarlar\u0131<\/strong>: Onkoloji cihaz pazar\u0131 y\u0131ll\u0131k %8 b\u00fcy\u00fcyor<\/li>\n<\/ul>\n<h2>\ud83c\udfaf Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %5&#8217;inden fazlas\u0131n\u0131 NVCR gibi y\u00fcksek volatiliteye sahip biyotek hisselerine ay\u0131rmay\u0131n<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Tek seferde b\u00fcy\u00fck al\u0131m yerine haftal\u0131k k\u00fc\u00e7\u00fck al\u0131mlar yap\u0131n<\/li>\n<li><strong>Fiyat Uyar\u0131lar\u0131 Kurun<\/strong>: 11,50 $ destek ve 15 $ diren\u00e7 \u00f6nemli seviyeler<\/li>\n<li><strong>Ekim Ay\u0131n\u0131 Bekleyin<\/strong>: 3. \u00e7eyrek kazan\u00e7 a\u00e7\u0131klamas\u0131 sonras\u0131 pozisyon olu\u015fturmay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li>\n<\/ol>\n<p>Ve t\u00fcccarlar\u0131n bilgelik s\u00f6z\u00fc: &#8220;D\u00fc\u015fen bir biyotek hissesini yakalamaya \u00e7al\u0131\u015fmak d\u00fc\u015fen bir b\u0131\u00e7a\u011f\u0131 yakalamaya benzer\u2014bazen sap\u0131 tutars\u0131n\u0131z, bazen b\u0131\u00e7a\u011f\u0131. \u00d6nce hareketin durmas\u0131n\u0131 beklemek daha iyidir!&#8221;<\/p>\n<h2>\u2705 NovoCure Limited (NVCR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Platformunuzu Se\u00e7in<\/td>\n<td>NASDAQ hisseleri sunan ve makul \u00fccretlere sahip oldu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Do\u011frulamay\u0131 Tamamlay\u0131n<\/td>\n<td>Hesap onay\u0131 i\u00e7in kimli\u011finizi haz\u0131r bulundurun<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Hesab\u0131n\u0131z\u0131 Fonlay\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>&#8220;NVCR&#8221; Aray\u0131n<\/td>\n<td>\u015eirket ad\u0131 yerine borsa sembol\u00fcn\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Limit Emri Verin<\/td>\n<td>Piyasa fiyat\u0131 yerine giri\u015f fiyat\u0131n\u0131z\u0131 se\u00e7in<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Emir Detaylar\u0131n\u0131 G\u00f6zden Ge\u00e7irin<\/td>\n<td>Komisyon \u00fccretleri ve toplam maliyeti kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Al\u0131m\u0131 Ger\u00e7ekle\u015ftirin<\/td>\n<td>Onaylay\u0131n ve emrin ger\u00e7ekle\u015fmesini bekleyin<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>Fiyat Uyar\u0131lar\u0131 Kurun<\/td>\n<td>Yat\u0131r\u0131m\u0131n\u0131z\u0131 s\u00fcrekli kontrol etmeden takip edin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option NVCR Ticareti \u0130\u00e7in Neden Mant\u0131kl\u0131?<\/h2>\n<p>NovoCure ile denemek isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in Pocket Option, biyotek ticareti i\u00e7in ideal birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Minimum Para Yat\u0131rma<\/strong>: Sadece 5 $ ile fraksiyonel hisse al\u0131m\u0131 yapabilirsiniz\u2014pahal\u0131 hisseler i\u00e7in ideal<\/li>\n<li><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: Tek belge KYC ile dakikalar i\u00e7inde i\u015flem yapabilirsiniz, g\u00fcnler de\u011fil<\/li>\n<li><strong>Esnek Para \u00c7ekme<\/strong>: Kripto dahil 100&#8217;den fazla se\u00e7enek, volatil hareketlerde h\u0131zl\u0131 kar alma i\u00e7in m\u00fckemmel<\/li>\n<li><strong>Ger\u00e7ek Zamanl\u0131 Uyar\u0131lar<\/strong>: Piyasay\u0131 an\u0131nda etkileyen biyotek haberlerini yakalamak i\u00e7in kritik<\/li>\n<\/ul>\n<p>D\u00fc\u015f\u00fck giri\u015f engelleri ve geli\u015fmi\u015f ara\u00e7lar\u0131n birle\u015fimi, Pocket Option&#8217;u NVCR gibi yenilik\u00e7i ama volatil hisseler i\u00e7in \u00f6zellikle uygun k\u0131lar.<\/p>\n<h2>\ud83c\udfe2 2025&#8217;te NovoCure: Onkolojide Yenilik\u00e7i Bir Devrimci<\/h2>\n<p>NovoCure, T\u00fcm\u00f6r Tedavi Alanlar\u0131 teknolojisi ile kanser tedavisinde \u00f6nc\u00fc konumdad\u0131r\u2014elektrik alanlar\u0131 kullanarak kanser h\u00fccresi b\u00f6l\u00fcnmesini bozan invazif olmayan bir y\u00f6ntem. Geleneksel kemoterapi veya radyasyondan farkl\u0131 olarak, TTFields terapisi daha az yan etki sunar ve di\u011fer tedavilerle birlikte kullan\u0131labilir.<\/p>\n<p>\u015eirket \u015fu anda d\u00fcnya \u00e7ap\u0131nda 35.000&#8217;den fazla hastay\u0131 tedavi etmekte ve be\u015f devam eden klinik denemeye sahiptir. \u0130svi\u00e7re&#8217;deki yeni global merkezlerine ta\u015f\u0131nmalar\u0131, uluslararas\u0131 geni\u015fleme planlar\u0131n\u0131n g\u00f6stergesidir.<\/p>\n<p><strong>\u0130lgin\u00e7 Bilgi<\/strong>: 2025 y\u0131l\u0131nda NovoCure ara\u015ft\u0131rma ekibi, TTFields teknolojisinin sadece kanser h\u00fccresi b\u00f6l\u00fcnmesini bozmakla kalmay\u0131p, baz\u0131 imm\u00fcnoterapilerin etkinli\u011fini art\u0131rd\u0131\u011f\u0131na dair bulgular ke\u015ffetti\u2014bu, tamamen yeni tedavi kombinasyonlar\u0131 ve pazar f\u0131rsatlar\u0131n\u0131n kap\u0131s\u0131n\u0131 a\u00e7abilir.<\/p>\n"},"faq":[{"question":"NovoCure Limited hisseleri nereden al\u0131nabilir?","answer":"NovoCure Limited hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir ve bir\u00e7ok \u00e7evrimi\u00e7i arac\u0131 kurum ve yat\u0131r\u0131m platformu \u00fczerinden sat\u0131n al\u0131nabilir."},{"question":"NVCR hisseleri ne kadar risklidir?","answer":"NVCR hisseleri y\u00fcksek volatiliteye sahiptir (%18,93), bu nedenle fiyat dalgalanmalar\u0131 g\u00fcnl\u00fck \u00b12,35 $ civar\u0131ndad\u0131r. Y\u00fcksek risk i\u00e7erir ve yat\u0131r\u0131mc\u0131lar\u0131n dikkatli olmas\u0131 gerekir."},{"question":"NovoCure'nin b\u00fcy\u00fcme potansiyeli nedir?","answer":"Analistler 2025-2030 aras\u0131nda NVCR hisselerinin \u00f6nemli b\u00fcy\u00fcme g\u00f6sterece\u011fini \u00f6ng\u00f6r\u00fcyor. 2025 sonunda fiyat\u0131n 13-65 $ aras\u0131nda de\u011fi\u015febilece\u011fi tahmin ediliyor."},{"question":"NovoCure'nin tedavi teknolojisi nedir?","answer":"NovoCure, T\u00fcm\u00f6r Tedavi Alanlar\u0131 (TTFields) teknolojisi ile elektrik alanlar\u0131 kullanarak kanser h\u00fccrelerinin b\u00f6l\u00fcnmesini engelleyen yenilik\u00e7i ve invazif olmayan bir tedavi sunmaktad\u0131r."},{"question":"Yeni ba\u015flayanlar NVCR hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Yeni ba\u015flayanlar portf\u00f6ylerinin %5'inden fazlas\u0131n\u0131 NVCR gibi y\u00fcksek volatiliteye sahip hisselere ay\u0131rmamal\u0131, k\u00fc\u00e7\u00fck miktarlarla d\u00fczenli al\u0131m yapmal\u0131 ve fiyat uyar\u0131lar\u0131 kurarak piyasay\u0131 takip etmelidir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"NovoCure Limited hisseleri nereden al\u0131nabilir?","answer":"NovoCure Limited hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir ve bir\u00e7ok \u00e7evrimi\u00e7i arac\u0131 kurum ve yat\u0131r\u0131m platformu \u00fczerinden sat\u0131n al\u0131nabilir."},{"question":"NVCR hisseleri ne kadar risklidir?","answer":"NVCR hisseleri y\u00fcksek volatiliteye sahiptir (%18,93), bu nedenle fiyat dalgalanmalar\u0131 g\u00fcnl\u00fck \u00b12,35 $ civar\u0131ndad\u0131r. Y\u00fcksek risk i\u00e7erir ve yat\u0131r\u0131mc\u0131lar\u0131n dikkatli olmas\u0131 gerekir."},{"question":"NovoCure'nin b\u00fcy\u00fcme potansiyeli nedir?","answer":"Analistler 2025-2030 aras\u0131nda NVCR hisselerinin \u00f6nemli b\u00fcy\u00fcme g\u00f6sterece\u011fini \u00f6ng\u00f6r\u00fcyor. 2025 sonunda fiyat\u0131n 13-65 $ aras\u0131nda de\u011fi\u015febilece\u011fi tahmin ediliyor."},{"question":"NovoCure'nin tedavi teknolojisi nedir?","answer":"NovoCure, T\u00fcm\u00f6r Tedavi Alanlar\u0131 (TTFields) teknolojisi ile elektrik alanlar\u0131 kullanarak kanser h\u00fccrelerinin b\u00f6l\u00fcnmesini engelleyen yenilik\u00e7i ve invazif olmayan bir tedavi sunmaktad\u0131r."},{"question":"Yeni ba\u015flayanlar NVCR hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Yeni ba\u015flayanlar portf\u00f6ylerinin %5'inden fazlas\u0131n\u0131 NVCR gibi y\u00fcksek volatiliteye sahip hisselere ay\u0131rmamal\u0131, k\u00fc\u00e7\u00fck miktarlarla d\u00fczenli al\u0131m yapmal\u0131 ve fiyat uyar\u0131lar\u0131 kurarak piyasay\u0131 takip etmelidir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NovoCure Limited (NVCR) Hisseleri Nas\u0131l Al\u0131n\u0131r - NovoCure Limited (NVCR) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NovoCure Limited (NVCR) Hisseleri Nas\u0131l Al\u0131n\u0131r - NovoCure Limited (NVCR) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T14:27:45+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"NovoCure Limited (NVCR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; NovoCure Limited (NVCR) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T14:27:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/\",\"name\":\"NovoCure Limited (NVCR) Hisseleri Nas\u0131l Al\u0131n\u0131r - NovoCure Limited (NVCR) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"datePublished\":\"2025-08-25T14:27:45+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NovoCure Limited (NVCR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; NovoCure Limited (NVCR) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NovoCure Limited (NVCR) Hisseleri Nas\u0131l Al\u0131n\u0131r - NovoCure Limited (NVCR) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/","og_locale":"tr_TR","og_type":"article","og_title":"NovoCure Limited (NVCR) Hisseleri Nas\u0131l Al\u0131n\u0131r - NovoCure Limited (NVCR) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T14:27:45+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"NovoCure Limited (NVCR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; NovoCure Limited (NVCR) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T14:27:45+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/","name":"NovoCure Limited (NVCR) Hisseleri Nas\u0131l Al\u0131n\u0131r - NovoCure Limited (NVCR) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","datePublished":"2025-08-25T14:27:45+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"NovoCure Limited (NVCR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; NovoCure Limited (NVCR) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":348365,"slug":"how-to-buy-novocure-limited","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu NovoCure Limited (NVCR) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu NovoCure Limited (NVCR)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-novocure-limited\/"},"pt_AA":{"locale":"pt_AA","id":348361,"slug":"how-to-buy-novocure-limited","post_title":"Como comprar a\u00e7\u00f5es da NovoCure Limited (NVCR) - Investimento em a\u00e7\u00f5es da NovoCure Limited (NVCR)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-novocure-limited\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/348362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=348362"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/348362\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334081"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=348362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=348362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=348362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}